ID   A2780/cmv
AC   CVCL_A5AB
DR   cancercelllines; CVCL_A5AB
DR   Wikidata; Q107113314
RX   PubMed=9924699;
RX   PubMed=12093475;
CC   Population: African American.
CC   Characteristics: Control cell line for A2780/m175 (Cellosaurus=CVCL_A5AC), A2780/m248 (Cellosaurus=CVCL_A5AD) and A2780/m273 (Cellosaurus=CVCL_A5AE) (PubMed=9924699).
CC   Sequence variation: Mutation; HGNC; HGNC:795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu365Lys (c.1093G>A); ClinVar=VCV000419222; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:17271; RRAS2; Simple; p.Gln72Leu (c.215A>T); ClinVar=VCV000009447; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 10-04-25; Version: 9
//
RX   PubMed=9924699; DOI=10.1097/00002371-199901000-00007;
RA   Sleijfer S., Le T.K.P., de Jong S., Timmer-Bosscha H., Withoff S.,
RA   Mulder N.H.;
RT   "Combined cytotoxic effects of tumor necrosis factor-alpha with
RT   various cytotoxic agents in tumor cell lines that are drug resistant
RT   due to mutated p53.";
RL   J. Immunother. 22:48-53(1999).
//
RX   PubMed=12093475; DOI=10.1016/S0006-2952(02)00983-8;
RA   Fokkema E., Groen H.J.M., Helder M.N., de Vries E.G.E., Meijer C.;
RT   "JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to
RT   platinum-DNA adduct formation, glutathione levels and p53 status in
RT   human tumour cell lines with different sensitivities to cisplatin.";
RL   Biochem. Pharmacol. 63:1989-1996(2002).
//